Exact Mass: 365.06342240000004

Exact Mass Matches: 365.06342240000004

Found 38 metabolites which its exact mass value is equals to given mass value 365.06342240000004, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Benzoylprop-ethyl

ethyl 2-[N-(3,4-dichlorophenyl)-1-phenylformamido]propanoate

C18H17Cl2NO3 (365.05854320000003)

metolazone

Metolazone (Zaroxolyn)

C16H16ClN3O3S (365.0600856)

indapamide

Indapamide (Lozol)

C16H16ClN3O3S (365.0600856)

C - Cardiovascular system > C03 - Diuretics > C03B - Low-ceiling diuretics, excl. thiazides > C03BA - Sulfonamides, plain D045283 - Natriuretic Agents > D004232 - Diuretics > D049993 - Sodium Chloride Symporter Inhibitors C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D049990 - Membrane Transport Modulators CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3822; ORIGINAL_PRECURSOR_SCAN_NO 3820 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3835; ORIGINAL_PRECURSOR_SCAN_NO 3834 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3799; ORIGINAL_PRECURSOR_SCAN_NO 3798 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3832; ORIGINAL_PRECURSOR_SCAN_NO 3829 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3815; ORIGINAL_PRECURSOR_SCAN_NO 3812 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3819; ORIGINAL_PRECURSOR_SCAN_NO 3817 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7807; ORIGINAL_PRECURSOR_SCAN_NO 7802 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7842; ORIGINAL_PRECURSOR_SCAN_NO 7839 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7849; ORIGINAL_PRECURSOR_SCAN_NO 7846 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7871; ORIGINAL_PRECURSOR_SCAN_NO 7868 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7902; ORIGINAL_PRECURSOR_SCAN_NO 7900 CONFIDENCE standard compound; EAWAG_UCHEM_ID 3686 CONFIDENCE standard compound; INTERNAL_ID 1111

Indapamide

4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1-yl)-3-sulfamoylbenzamide

C16H16ClN3O3S (365.0600856)

Indapamide is only found in individuals that have used or taken this drug. It is a benzamide-sulfonamide-indole. It is called a thiazide-like diuretic but structure is different enough (lacking the thiazo-ring) so it is not clear that the mechanism is comparable. [PubChem]Indapamide blocks the slow component of delayed rectifier potassium current (IKs) without altering the rapid component (IKr) or the inward rectifier current. Specifically it blocks or antagonizes the action the proteins KCNQ1 and KCNE1. Indapamide is also thought to stimulate the synthesis of the vasodilatory hypotensive prostaglandin PGE2. C - Cardiovascular system > C03 - Diuretics > C03B - Low-ceiling diuretics, excl. thiazides > C03BA - Sulfonamides, plain D045283 - Natriuretic Agents > D004232 - Diuretics > D049993 - Sodium Chloride Symporter Inhibitors C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D049990 - Membrane Transport Modulators

Metolazone

7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulphonamide

C16H16ClN3O3S (365.0600856)

Metolazone is only found in individuals that have used or taken this drug. It is a quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. [PubChem]The actions of metolazone result from interference with the renal tubular mechanism of electrolyte reabsorption. Metolazone acts primarily to inhibit sodium reabsorption at the cortical diluting site and to a lesser extent in the proximal convoluted tubule. Sodium and chloride ions are excreted in approximately equivalent amounts. The increased delivery of sodium to the distal tubular exchange site results in increased potassium excretion. Metolazone does not inhibit carbonic anhydrase. The antihypertensive mechanism of action of metolazone is not fully understood but is presumed to be related to its saluretic and diuretic properties. C - Cardiovascular system > C03 - Diuretics > C03B - Low-ceiling diuretics, excl. thiazides > C03BA - Sulfonamides, plain D045283 - Natriuretic Agents > D004232 - Diuretics > D049993 - Sodium Chloride Symporter Inhibitors C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D049990 - Membrane Transport Modulators

Fludarabine

{[(2R,3S,4S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid

C10H13FN5O7P (365.05366100000003)

Fludarabine is only found in individuals that have used or taken this drug. Fludarabine (marketed as fludarabine phosphate under the trade name Fludara) is a chemotherapy drug used in the treatment of hematological malignancies. [Wikipedia]Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted. C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2150 - Ribonucleotide Reductase Inhibitor D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents Fludarabine (phosphate) is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.

Fludara

{[5-(6-amino-2-fluoro-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid

C10H13FN5O7P (365.05366100000003)

D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents

2-Hydroxy-4-(2-(tosyloxy)acetamido)benzoic acid

2-hydroxy-4-{2-[(4-methylbenzenesulfonyl)oxy]acetamido}benzoic acid

C16H15NO7S (365.05692)

p38 MAP Kinase Inhibitor

2-(4-chlorophenyl)-4-(4-fluorophenyl)-5-(pyridin-4-yl)-2,3-dihydro-1H-pyrazol-3-one

C20H13ClFN3O (365.07311300000003)

C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2150 - Ribonucleotide Reductase Inhibitor D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents Fludarabine (phosphate) is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.

Zidapamide

4-chloro-N-(1-methyl-1,3-dihydroisoindol-2-yl)-3-sulfamoylbenzamide

C16H16ClN3O3S (365.0600856)

C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic

4-[BIS(4-FLUOROPHENYL)METHYLENE]PIPERIDINE HYDROBROMIDE

C18H18BrF2N (365.05905920000004)

1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[[(trifluoromethyl)sulfonyl]oxy]-, phenylmethyl ester

C14H14F3NO5S (365.054475)

N-((5-(4-chloroquinazolin-6-yl)furan-2-yl)Methyl)-2-(Methylsulfonyl)ethanamine

C16H16ClN3O3S (365.0600856)

2-(2-Hydroxy-4-benzoyloxyphenyl)-5-chlorobenzotriazole

C19H12ClN3O3 (365.0567152)

Cefuroxime Sodium EP Impurity C

C15H15N3O6S (365.06815300000005)

Itazigrel

C18H14F3NO2S (365.06973000000005)

C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent C471 - Enzyme Inhibitor

2,2:6,2-Terpyridine-4,4,4-tricarboxylic acid

C18H11N3O6 (365.0647826)

(S)-Indapamide

C16H16ClN3O3S (365.0600856)

p38 MAP Kinase Inhibitor

C20H13ClFN3O (365.07311300000003)

8-Carboxy-2,4,6,9-tetrahydroxy-7-methyltetracen-5-olate

C20H13O7- (365.0661248)

[(1S)-2-[2-[(2R)-2-amino-2-carboxyethyl]selanyl-1H-imidazol-5-yl]-1-carboxyethyl]-trimethylazanium

C12H21N4O4Se+ (365.0727936)

tetracenomycin F1(1-)

C20H13O7- (365.0661248)

A hydroxy monocarboxylic acid anion that is the conjugate base of tetracenomycin F1, obtained by deprotonation of the carboxy group.

2-(2-bromo-4-tert-butylphenoxy)-N-(2-furanylmethyl)acetamide

C17H20BrNO3 (365.0626470000001)

N-[5-fluoro-2-(3-oxo-4H-quinoxalin-2-yl)phenyl]-2-thiophenecarboxamide

C19H12FN3O2S (365.06342240000004)

4-(2,3-Dihydro-1,4-benzodioxin-3-ylmethylamino)-3-nitrobenzenesulfonamide

C15H15N3O6S (365.06815300000005)

N(4)-acetylcytidine 5-monophosphate

C11H16N3O9P (365.0624136)

5-(3,4-Dimethoxyphenyl)-2-phenyl-4-thieno[2,3-d][1,3]oxazinone

C20H15NO4S (365.0721750000001)

2-Phenylbutanoic acid [2-(3,5-dichloroanilino)-2-oxoethyl] ester

C18H17Cl2NO3 (365.05854320000003)

2-(4-(Tert-butyl)benzamido)-4,5-dichlorobenzoic acid

C18H17Cl2NO3 (365.05854320000003)

1-(2-Furanylmethyl)-4-[oxo(thiophen-2-yl)methyl]-5-phenylpyrrolidine-2,3-dione

C20H15NO4S (365.0721750000001)

Benzoylprop-ethyl

C18H17Cl2NO3 (365.05854320000003)

S3I-201

2-Hydroxy-4-(2-(tosyloxy)acetamido)benzoic acid

C16H15NO7S (365.05692)

Afizagabar

C19H12FN3O2S (365.06342240000004)

Afizagabar (S44819) is a first-in-class, competitive, and selective antagonist at the GABA-binding site of the α5-GABAAR, with an IC50 of 585 nM for α5β2γ2 and a Ki of 66 nM for α5β3γ2. Afizagabar enhances hippocampal synaptic plasticity and exhibits pro-cognitive efficacy[1].

GYKI 52466 (dihydrochloride)

C17H17Cl2N3O2 (365.06977620000004)

GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research[1][2].